SAN MATEO, CA, BigHat Biosciences, a biotechnology company, has raised a $75 million Series B funding round, led by Section 32.
BigHat Biosciences, a biotechnology company developing safer, more effective antibody therapies for patients using machine learning and synthetic biology, has raised a $75 million Series B funding round, led by Section 32, with participation from new investors Amgen Ventures, Bristol Myers Squibb, Quadrille Capital, Gaingels, GRIDS Capital, among others.
The investment brings BigHat's total funding to date to $100 million. Prior investors Andreessen Horowitz, 8VC, and AME Cloud Ventures also contributed to this round
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about